Diagnosing the system, not just the patient: A rare alliance calls for reform

On Rare Cancers Awareness Day (26 June), Christine Cockburn, CEO of Rare Cancers Australia (RCA), and Paul Fenton, CEO of Icon Group AU, delve into the impact of their partnership which aims to redefine awareness and support for those battling rare cancers.

They bring forward the lived experience – stories of patients lost in a maze of misdiagnoses, delayed treatments, and bureaucratic dead ends. These are not edge cases; they are the everyday reality for too many Australians, bringing to light the urgent need for policy reforms to integrate precision medicine into mainstream healthcare.

With a health system under immense pressure – public hospitals strain, private sector viability issues, and industrial tensions rising – Cockburn tackles critical questions about where the Health Technology Assessment (HTA) Review truly sits on the Minister’s radar. Is reform still on the agenda, or has it been lost in the noise?

Fenton brings the conversation back to innovation. With one of the largest clinical trial footprints in private health, Icon is rewriting what’s possible for rare cancer patients. He paints a picture of a future where access to cutting-edge care isn’t dictated by postcode.

As the re-elected Labor government enters a new term with a powerful majority, Cockburn and Fenton outline their advocacy roadmap and what must happen to turn rhetoric into reform.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.